Fig. 8From: Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malariaMost common treatment emergent adverse events of any cause. Safety population. Data are % patients for adverse events occurring in > 3% of patients in any treatment group. AE, adverse eventBack to article page